Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY 5301 in Patients With an Anterior ST-Elevation Myocardial Infarction

NCT04837001 is registered in ClinicalTrials.gov with Faraday Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04837001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04837001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY 5301 in Patients With an Anterior ST-Elevation Myocardial Infarction
Lead sponsor
Faraday Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 2, 2022
Completion date
September 3, 2025
Enrollment
2,351 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction, percutaneous coronary revascularization, stemi